What question did this study set out to answer?

To evaluate the impact of relugolix on quality of life, treatment adherence, and adverse events in advanced prostate cancer patients.

March 4, 2026

Quality of life, adherence, and adverse events among patients with advanced prostate cancer treated with relugolix: 6-month results of the OPTYX multicenter registry.

Key Points

To evaluate the impact of relugolix on quality of life, treatment adherence, and adverse events in advanced prostate cancer patients.
Prospective multicenter observational study conducted in the US.
Patients were enrolled if they initiated treatment with relugolix ≤1 month prior to enrollment.
Quality of life was assessed using the FACT-P scale at baseline, 3 months, and 6 months, while adherence was measured using the SMAQ.
Quality of life scores remained stable at 6 months with a mean FACT-P score of 120.2.
95.8% adhered to taking relugolix on time, with 4.0% discontinuing when feeling bad.
Serious adverse events were uncommon, reported in 3.9% of patients.

Abstract

122 Background: Relugolix is the only oral androgen deprivation therapy FDA approved for advanced prostate cancer (PC), based on the phase 3 randomized HERO trial. Data on quality of life (QoL), adherence, and safety in real-world clinical practice are needed. Methods: OPTYX is a prospective multicenter observational study (NCT05467176) of US patients with PC initiating treatment with relugolix ≤1 month before enrollment; androgen receptor pathway inhibitors could be added or withdrawn at physician’s discretion. Patients with an intended treatment plan of 2 patients) were anemia (0.4%) and acute myocardial infarction (0.3%). AEs led to treatment discontinuation in 6.2% of patients; 2 deaths were reported (0.2%). Conclusions: Real-world utilization of relugolix was associated with stable QoL, high treatment adherence, and a low rate of serious AEs over the first 6 months. Patients will continue to be followed for a longer-term analysis in this ongoing study. Clinical trial information: NCT05467176 . Assessment Baseline 3 mo 6 mo FACT-P total score Mean (SD) 120.0 (20.34) 119.1 (20.54) 120.2 (19.95) Median (range) 122.8 (39-156) 112.9 (44-154) 124.0 (41-156) FACT-P physical well-being Mean (SD) 24.4 (3.99) 22.8 (4.57) 22.9 (4.25) Median (range) 26.0 (7-28) 24.0 (3-28) 24.0 (3-28) FACT-P social/family well-being Mean (SD) 22.7 (4.88) 22.3 (5.03) 22.6 (4.68) Median (range) 24.0 (4-28) 24.0 (0-28) 24.0 (0-28) FACT-P emotional well-being Mean (SD) 18.8 (4.03) 20.1 (3.70) 20.2 (3.77) Median (range) 20.0 (0-24) 21.0 (4-24) 21.0 (0-24) FACT-P functional well-being Mean (SD) 20.8 (6.19) 20.7 (5.84) 20.9 (5.72) Median (range) 22.0 (4-28) 22.0 (2-28) 22.0 (0-28) FACT-P prostate cancer subscale Mean (SD) 33.3 (7.84) 33.2 (7.48) 33.5 (7.28) Median (range) 34.0 (3-48)</ja

Bookmark

Quality of life, adherence, and adverse events among patients with advanced prostate cancer treated with relugolix: 6-month results of the OPTYX multicenter registry.

Key Points

Abstract

Cite This Study

Also Consider

Also Consider